ストックスクリーナーアプリを入手
2.296
0.04%
0.0010
前日終値:
$2.295
開ける：
$2.26
24時間の取引高:
39,879
Relative Volume:
1.76
時価総額：
$157.73M
収益：
-
当期純損益:
$-27.63M
株価収益率:
-7.175
EPS:
-0.32
ネットキャッシュフロー:
$-39.43M
1週間 パフォーマンス:
+4.36%
1か月 パフォーマンス:
+1.15%
6か月 パフォーマンス:
-15.28%
1年 パフォーマンス:
-17.71%
1日の値動き範囲:
$2.20
$2.30
1週間の範囲:
$2.20
$2.32
52週間の値動き範囲:
$1.75
$3.40
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
DRTS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| DRTS | 2.30 | 157.73M | 0 | -27.63M | -39.43M | -0.32 |
| VRTX | 450.35 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.65 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.57 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.09 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-04-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-04-08 | 開始されました | Piper Sandler | Overweight |
| 2022-04-04 | 開始されました | Citigroup | Buy |
Alpha Tau Medical Ltd (DRTS) 最新ニュース
Piper Sandler reaffirms OW rating on Alpha Tau Medical shares as 'multiple milestones' line up - Investing.com South Africa
Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Alpha Tau Medical Advances in Cancer Treatment Technology - TipRanks
Alpha Tau Medical Advances Cancer Treatment Pipeline, Reports $68.4M Cash Position | DRTS Stock News - StockTitan
Alpha Emitter Market Size Expected to Hit USD 1751.5 Million by 2032, Expanding at a 11.25% CAGR: VMR - EIN News
DRTSWAlpha Tau Medical Ltd. Warrant Latest Stock News & Market Updates - StockTitan
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Sees Significant Growth in Short Interest - MarketBeat
Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Grows By 30.5% - Defense World
Alpha Tau Medical to Showcase at Key Healthcare Conferences - TipRanks
Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference - The Manila Times
Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare Conference - Marketscreener.com
Alpha Tau to Participate in Citi’s 2024 Global Healthcare - GlobeNewswire
Alpha Tau CFO to Present Alpha DaRT Cancer Therapy at Major Healthcare Conferences | DRTS Stock News - StockTitan
Alpha Tau Medical to Hold Annual Shareholder Meeting - TipRanks
Alpha Tau Medical : Notice and proxy statement for the annual general meeting of shareholders of the Company to be held on December 17, 2024 Form 6 K - Marketscreener.com
Medical Lasers Market Growth and Technology 2024 - openPR
MasterCraft Boat Holdings, Inc. (NASDAQ:MCFT) Receives $19.20 Average Target Price from Analysts - Defense World
Spire Global, Inc. (NYSE:SPIR) Receives $13.67 Average Target Price from Brokerages - Defense World
Brinker International (NYSE:EAT) Sets New 52-Week High After Analyst Upgrade - Defense World
Invesco Solar ETF Target of Unusually High Options Trading (NYSEARCA:TAN) - Defense World
Traders Buy High Volume of Call Options on Nutrien (NYSE:NTR) - Defense World
Brokerages Set Silvaco Group, Inc. (NASDAQ:SVCO) PT at $20.83 - Defense World
Analysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) PT at $34.60 - Defense World
Orthofix Medical (NASDAQ:OFIX) and Alpha Tau Medical (NASDAQ:DRTS) Financial Contrast - Defense World
Top 230+ startups in Radiation Therapy Devices in Nov, 2024 - Tracxn
Comparing Alpha Tau Medical (NASDAQ:DRTS) and Beyond Air (NASDAQ:XAIR) - Defense World
Discover Alpha Tau Medical And 2 Other US Penny Stocks - Simply Wall St
Head-To-Head Review: Biotricity (NASDAQ:BTCY) vs. Alpha Tau Medical (NASDAQ:DRTS) - Defense World
HC Wainwright Reiterates "Buy" Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Alpha Tau Joins FDA Program to Advance Cancer Therapy - TipRanks
Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme - The Manila Times
Alpha Tau Announces Acceptance Into FDA’s Total Product - GlobeNewswire
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme - Yahoo Finance
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update - MarketBeat
Alpha Tau Medical (NASDAQ:DRTS) Stock Rating Reaffirmed by HC Wainwright - Defense World
Alpha Tau Medical shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com Canada
Alpha Tau’s Alpha DaRT Advances Lung Cancer Treatment - Yahoo Finance
HC Wainwright Reaffirms "Buy" Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Alpha Tau Medical shares maintain Buy rating from H.C. Wainwright - Investing.com
Alpha Emitter Market Size to witness nearly $1751.5 Million By 2032 - 대구포스트
Alpha Tau treats first lung cancer patient with radiation therapy in Jerusalem - Mugglehead
Alpha Tau Treats First Patient with Recurrent Lung Cancer - ForexTV.com
Alpha Tau Medical Ltd. Treats First Patient with Recurrent Lung Cancer - Marketscreener.com
Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer - Marketscreener.com
Radiopharmaceutical Market 2024 – Industry Opportunities, Challenges, Value Chain and Sales Channels Analysis 2032 | Clarity Pharmaceuticals - 대구포스트
Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Expands By 23.9% - MarketBeat
Alpha Emitter Market Outlook, Key Trends and Growth Projections from 2024 to 2032 - 대구포스트
Alpha Emitter Market on the Rise: A Study on its Growth Prospects - openPR
Point72 DIFC Ltd Acquires Shares of 18,774 ChampionX Co. (NASDAQ:CHX) - Defense World
Alpha Tau Medical Ltd.FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT in Immunocompromised Patients with Recurrent cSCC - Marketscreener.com
Alpha Tau Medical Ltd (DRTS) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):